[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2023005192A - Composicion que comprende una combinacion de inhibidor de punto de control inmunitario y conjugado de anticuerpo-amatoxina para uso en la terapia del cancer. - Google Patents

Composicion que comprende una combinacion de inhibidor de punto de control inmunitario y conjugado de anticuerpo-amatoxina para uso en la terapia del cancer.

Info

Publication number
MX2023005192A
MX2023005192A MX2023005192A MX2023005192A MX2023005192A MX 2023005192 A MX2023005192 A MX 2023005192A MX 2023005192 A MX2023005192 A MX 2023005192A MX 2023005192 A MX2023005192 A MX 2023005192A MX 2023005192 A MX2023005192 A MX 2023005192A
Authority
MX
Mexico
Prior art keywords
composition
immune checkpoint
checkpoint inhibitor
antibody
combination
Prior art date
Application number
MX2023005192A
Other languages
English (en)
Inventor
CHRISTOPH MüLLER
Andreas Pahl
Torsten Hechler
Susanne Werner-Simon
Michael Kulke
Original Assignee
Heidelberg Pharma Res Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heidelberg Pharma Res Gmbh filed Critical Heidelberg Pharma Res Gmbh
Publication of MX2023005192A publication Critical patent/MX2023005192A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6831—Fungal toxins, e.g. alpha sarcine, mitogillin, zinniol or restrictocin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente solicitud se refiere a una composición que comprende (a) al menos un inhibidor de punto de control inmunitario y (b) al menos un conjugado, en donde dicho conjugado comprende (i) un resto de unión a diana, (ii) al menos una amatoxina y, (iii) opcionalmente, al menos un enlazador que conecta dicho resto de unión a diana con dicha al menos una amatoxina. La presente solicitud se refiere además a dicha composición para uso en el tratamiento de un paciente con cáncer, y a una formulación farmacéutica que comprende dicha composición y excipientes adicionales, así como métodos de producción y uso de dicha composición.
MX2023005192A 2020-11-04 2021-11-04 Composicion que comprende una combinacion de inhibidor de punto de control inmunitario y conjugado de anticuerpo-amatoxina para uso en la terapia del cancer. MX2023005192A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20205794 2020-11-04
PCT/EP2021/080688 WO2022096604A1 (en) 2020-11-04 2021-11-04 Composition comprising a combination of immune checkpoint inhibitor and antibody-amatoxin conjugate for use in cancer therapy

Publications (1)

Publication Number Publication Date
MX2023005192A true MX2023005192A (es) 2023-05-15

Family

ID=73288362

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023005192A MX2023005192A (es) 2020-11-04 2021-11-04 Composicion que comprende una combinacion de inhibidor de punto de control inmunitario y conjugado de anticuerpo-amatoxina para uso en la terapia del cancer.

Country Status (10)

Country Link
EP (1) EP4240424A1 (es)
JP (1) JP2023548522A (es)
KR (1) KR20230104653A (es)
CN (1) CN116744969A (es)
AU (1) AU2021373298A1 (es)
CA (1) CA3195572A1 (es)
CL (1) CL2023001266A1 (es)
IL (1) IL302034A (es)
MX (1) MX2023005192A (es)
WO (1) WO2022096604A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR125130A1 (es) * 2021-03-19 2023-06-14 Heidelberg Pharma Res Gmbh Conjugados de amatoxina y anticuerpo específicos de linfocitos b
US20240165257A1 (en) 2022-11-01 2024-05-23 Heidelberg Pharma Research Gmbh Anti-gucy2c antibody and uses thereof
WO2024189048A1 (en) 2023-03-13 2024-09-19 Heidelberg Pharma Research Gmbh Subcutaneously administered antibody-drug conjugates for use in cancer treatment

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
EP1212422B1 (en) 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
EP2161336B2 (en) 2005-05-09 2017-03-29 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
ES2616355T3 (es) 2007-06-18 2017-06-12 Merck Sharp & Dohme B.V. Anticuerpos para el receptor humano de muerte programada PD-1
DE202007018529U1 (de) 2007-07-07 2008-12-04 Chamalow S.A. Implantierbarer Funkfrequenzdefibrillator R.F.
CN101970499B (zh) 2008-02-11 2014-12-31 治疗科技公司 用于肿瘤治疗的单克隆抗体
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
SI3192529T1 (sl) 2009-04-08 2020-07-31 Faulstich, Heinz Dr. Z amatoksinom ojačane vezne komponente terapevtske celične površine, zasnovane za zdravljenje tumorjev
EP3041828B1 (en) 2013-09-06 2018-05-23 Aurigene Discovery Technologies Limited 1,3,4-oxadiazole and 1,3,4-thiadiazole derivatives as immunomodulators
BR112017019300B1 (pt) 2015-03-09 2023-02-23 Heidelberg Pharma Gmbh Conjugado de fórmula genérica (ama l x s)n ab, método para sintetizar um conjugado de fórmula genérica (ama l x s)n ab, kit, composição farmacêutica e uso da composição farmacêutica
EP3222292A1 (en) 2016-03-03 2017-09-27 Heidelberg Pharma GmbH Amanitin conjugates
AU2017380099B2 (en) 2016-12-23 2024-07-11 Heidelberg Pharma Research Gmbh Amanitin antibody conjugates
CN110691790A (zh) 2017-06-02 2020-01-14 勃林格殷格翰国际有限公司 抗癌联合治疗
JP2021521202A (ja) * 2018-04-13 2021-08-26 ハイデルベルク ファルマ リサーチ ゲゼルシャフト ミット ベシュレンクテル ハフツング 固形腫瘍の治療のための標的化されたアマトキシン複合体
PL3830132T3 (pl) 2018-07-31 2023-04-17 Heidelberg Pharma Research Gmbh Humanizowane przeciwciała przeciwko psma

Also Published As

Publication number Publication date
KR20230104653A (ko) 2023-07-10
WO2022096604A1 (en) 2022-05-12
EP4240424A1 (en) 2023-09-13
JP2023548522A (ja) 2023-11-17
CL2023001266A1 (es) 2023-12-15
CA3195572A1 (en) 2022-05-12
AU2021373298A1 (en) 2023-06-08
CN116744969A (zh) 2023-09-12
IL302034A (en) 2023-06-01

Similar Documents

Publication Publication Date Title
MX2023005192A (es) Composicion que comprende una combinacion de inhibidor de punto de control inmunitario y conjugado de anticuerpo-amatoxina para uso en la terapia del cancer.
MX2022009044A (es) Conjugado de farmaco de derivado de eribulin, metodo de preparacion y aplicacion del mismo en medicina.
BR112018067379A2 (pt) conjugado anticorpo-droga, composição, método para tratamento de um paciente que tem ou corre o risco de ter um câncer, para produzir o conjugado anticorpo-droga ou a composição, para determinar se um paciente será responsivo a um tratamento com o conjugado anticorpo-droga ou a composição, e, uso de um conjugado anticorpo-droga ou de uma composição.
MX2022015695A (es) Medicina de camptotecina con alta unidad de conexion hidrofila y conjugado de la misma.
EP4241847A3 (en) Improved cell-targeting binding molecule
WO2020236825A3 (en) Mcl-1 inhibitor antibody-drug conjugates and methods of use
MX2021009199A (es) Conjugado de farmaco de dos ligandos y uso del mismo.
BR112023006337A2 (pt) Produto farmacêutico, uso de um conjugado anticorpo anti-her2-fármaco ou um inibidor seletivo de parp1, e, método de tratamento do câncer
MX2020009842A (es) Uso de conjugados de anticuerpo-farmaco que comprenden agentes interruptores de tubulina para tratar tumor solido.
MX2022012351A (es) Administracion conjunta de mirdametinib y lifirafenib para uso en el tratamiento de canceres.
CA3198996A1 (en) Bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
EA201690321A1 (ru) Применение иммуноконъюгата антитела к muc1 и майтанзиноида для лечения солидных опухолей
MX2022000430A (es) Administracion de agonista de sting e inhibidores de puntos de control.
PH12021551276A1 (en) Combination therapy for the treatment of cancer
BR0309226A (pt) Métodos para a produção de um efeito de danificação vascular em um animal de sangue quente, e para o tratamento de um câncer envolvendo um tumor sólido em um animal de sangue quente, composição farmacêutica, kit, e, usos de zd6126 ou de um seu sal farmaceuticamente aceitável, e de zd1839 ou de um seu sal farmaceuticamente aceitável
MX2021015447A (es) Métodos de tratamiento del cáncer dirigidos a tumores fríos.
JOP20200014A1 (ar) توليفة علاجية لمثبط كيناز تيروزين egfr من الجيل الثالث ومثبط raf
MX2024003277A (es) Conjugado de anticuerpo-farmaco para usarse en metodos de tratamiento del cancer resistente a la quimioterapia.
MX2021001832A (es) Conjugados para su uso en metodos de tratamiento del cancer.
MX2023010512A (es) Agentes de union multiespecificos contra cd40 y cd137 en terapia.
MX2021013391A (es) Conjugado de anticuerpo anti-bcma, composiciones que comprenden el mismo, y metodos de fabricacion y uso del mismo.
WO2023172629A3 (en) Anticancer maleimide derivatives for use with immune checkpoint blockade
BRPI0518619A2 (pt) mÉtodo de tratar cÂncer em um mamÍfero, combinaÇço farmacÊutica, uso de uma composiÇço ou combinaÇço farmacÊutica e composiÇço imunogÊnica
ZA202201446B (en) Methods of treating multifocal cancer
ZA202101990B (en) Sulfomaleimide-based linkers and corresponding conjugates